[Form 4] RB Global, Inc. Insider Trading Activity
Rhea-AI Filing Summary
RB Global, Inc. (RBA) — Form 4 insider filing. Director Carol Stephenson reported three transactions dated 06/20/2025, all coded “A” for acquisition and all involving dividend-equivalent rights (DERs) rather than common shares.
- DSU-related DERs: 11 rights acquired at $0 exercise price; aggregate DERs held after the transaction: 150.
- 2024 RSU-related DERs: 8 rights acquired at $0; aggregate balance: 42.
- 2025 RSU-related DERs: 5 rights acquired at $0; aggregate balance: 5.
Each DER gives the holder the economic equivalent of one RBA common share and vests concurrently with the underlying deferred share units (DSUs) or restricted share units (RSUs). No sales, disposals, or cash purchases were reported, and no price was paid for the rights.
Materiality assessment: The total of 24 newly accrued rights corresponds to 24 potential common shares, a de minimis amount relative to RBA’s outstanding share count. The filing represents routine accrual of dividend equivalents under existing equity awards and does not signal a directional view on the stock. Therefore, the information is considered neutral and non-material for most investors.
Positive
- None.
Negative
- None.
Insights
TL;DR: Routine accrual of 24 dividend-equivalent rights; negligible ownership change; no investment signal.
The Form 4 records automatic dividend-equivalent credits to Ms. Stephenson’s existing DSU and RSU balances. No open-market purchase or sale occurred, and the economic exposure increases by less than 0.0001 % of shares outstanding. Such transactions are common after dividend payments and carry no implications for cash flow or capital allocation. I classify the market impact as neutral.
TL;DR: Governance-routine equity bookkeeping; disclosure compliant; no red flags.
The filing demonstrates timely compliance with Section 16 reporting. Dividend-equivalent rights align director incentives with shareholders without immediate dilution or cash outlay. There are no indications of preferential treatment or 10b5-1 activity. Overall governance impact is negligible.